HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT) Files An 8-K Shareholder Director NominationsItem 5.08 Shareholder Director Nominations
On April 11, 2017, the Board of Directors of Helius Medical Technologies, Inc (the “Company”) determined that the Company’s 2017 Annual Meeting of Shareholders (the “Annual Meeting”) will be held on June 5, 2017 at 10:00 a.m. local time at Sheraton Bucks County Hotel, 400 Oxford Valley Road, Langhorne, PA 19047, or at such other location as the Board may determine and set forth in the Company’s proxy statement for the Annual Meeting. The Board also set April 12, 2017 as the record date for determining shareholders entitled to receive notice of, and vote at, the meeting.
Because the Annual Meeting will be held more than 30 days prior to the date of the anniversary of the Company’s 2016 Annual Meeting of Shareholders, the deadline for any shareholder proposal or shareholder nomination under the rules of the Securities and Exchange Commission (the “SEC”) listed in the Company’s 2016 Proxy Statement on Schedule 14A, as filed with the SEC on August 16, 2016, is no longer applicable. Any such shareholder proposal or nomination, including any notice on Schedule 14N, intended to be considered for inclusion in the Company’s proxy materials for the Annual Meeting, must be received by the Company at its principal executive offices by no later than April 21, 2017, and directed to the attention of the Company’s Secretary. Other requirements for inclusion in the Company’s proxy materials are set forth in the rules and regulations promulgated by the SEC and the Company’s bylaws. Shareholders may contact the Company’s Secretary to obtain a copy of the relevant bylaw provisions regarding the requirements for making shareholder nominations and proposals.
2
About HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT)
Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. The device, when used in combination with physiotherapy, is designed to enhance the brain’s ability to compensate for damage due to trauma or disease. The Company’s PoNS device is designed to induce cranial nerve non-invasive neuromodulation through an increase in stimulation of the facial and trigeminal nerves, which innervate the tongue. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation. The PoNS device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue. HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT) Recent Trading Information
HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT) closed its last trading session up +0.01 at 1.57 with 2,975 shares trading hands.